Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients

AIDS

Volumn 14, Issue 8, 2000, Pages 987-993

  Dupont, Caroline ^a   Vasseur, Emmanuelle ^a   Beauchet, Alain ^a   Aegerter, Philippe ^a   Berthé, Huguette ^a   De Truchis, Pierre ^b   Zucman, David ^c   Rouveix, Elisabeth ^a   Saiag, Philippe ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c FOCH HOSPITAL   (France)

Author keywords

Cohort study; HIV protease inhibitors; Kaposi's sarcoma

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SARCOMA, KAPOSI; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034035012     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005260-00010     Document Type: Article

References (24)

1. 1. Brodt HR, Kamps BS, Helm EB, Schofer H, Mitrou P. Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 1998, 12:1475-1481.
2. 2. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet 1996, 348:587-591.
3. 3. Murphy PM. Pirated genes in Kaposi's sarcoma. Nature 1997, 385:296-299.
4. 4. Yarchoan R. Therapy for Kaposi's sarcoma: recent advances and experimental approaches. J Acquir Immune Defic Syndr 1999, 21 (suppl 1):S66-S73.
5. 5. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999, 21 (suppl 1):S34-S41.
6. 6. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998, 280:72-77.
7. 7. Dupin N, Rubin de Cervens V, Corin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Dermatol 1999, 140:875-881.
8. 8. De Milito A, Catucci M, Venturi G, et al. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1-and human herpesvirus 8-coinfected patients. J Med Virol 1999, 57:140-144.
9. 9. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998, 12:F45-F49.
10. 10. Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechere M. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 1998, 38:594-598.
11. 11. Tavio M, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U. Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol 1998, 9:923.
12. 12. Harindra V, Foley E. Highly active antiretroviral therapy. Lancet 1998, 351:1058-1059.
13. 13. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997, 11:1895-1896.
14. 14. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989, 7:1201-1207.
15. 15. Saiag P, Pavlovic M, Clerici T, et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. Kaposi's Sarcoma ANRS Study Group. Agence Nationale de Recherches sur le SIDA. AIDS 1998, 12:2169-2176.
16. 16. Little RF, Pluda JM, Feigal E, Yarchoan R. The challenge of designing clinical trials for AIDS-related Kaposi's sarcoma. Oncology (Huntingt) 1998, 12:871-884.
17. 17. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997, 15:3085-3092.
18. 18. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 1997, 11:1327-1332.
19. 19. Boivin G, Gaudreau A, Toma E, et al. Human herpesvirus 8 DNA load in leukocytes of human immunodeficiency virus-infected subjects: correlation with the presence of Kaposi's sarcoma and response to anticytomegalovirus therapy. Antimicrob Agents Chemother 1999, 43:377-380.
20. 20. Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs. Blood 1996, 88:297-301.
21. 21. Whitby D, Howard MR, Tenant-Flowers M, et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995, 346:799-802.
22. 22. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997, 99:2082-2086.
23. 23. Fiorelli V, Barillari G, Toschi E, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999, 162:1165-1170.
24. 24. Penn I. Kaposi's sarcoma in transplant recipients. Transplantation 1997, 64:669-673.